Blockade of fast A-type and TEA-sensitive potassium channels provide an antiparkinsonian effect in a 6-OHDA animal model

References

1. ↵
   1. Dauer W,
   2. Przedborski S

   (2003) Parkinson’s disease:mechanisms and models. Neuron 39, 889–909.
2. ↵
   1. Wang Y,
   2. Yang PL,
   3. Tang JF,
   4. Lin JF,
   5. Cai XH,
   6. Wang XT,
   7. et al.

   (2008) Potassium channels:possible new therapeutic targets in Parkinson’s disease. Med Hypotheses 71, 546–550.
3. ↵
   1. Mathie A,
   2. Wooltorton JR,
   3. Watkins CS

   (1998) Voltage-activated potassium channels in mammalian neurons and their block by novel pharmacological agents. Gen Pharmacol 30, 13–24.
4. ↵
   1. Shieh CC,
   2. Coghlan M,
   3. Sullivan JP,
   4. Gopalakrishnan M

   (2000) Potassium channels:molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 52, 557–594.
5. ↵
   1. Wang G,
   2. Zeng J,
   3. Ren R,
   4. Chen S

   (2008) Potassium channels in the basal ganglia:promising new targets for the treatment of Parkinson’s disease. Front Biosci 13, 3685–3698.
6. ↵
   1. Wang X,
   2. Xiao AY,
   3. Ichinose T,
   4. Yu SP

   (2000) Effects of tetraethylammonium analogs on apoptosis and membrane currents in cultured cortical neurons. J Pharmacol Exp Ther 295, 524–530.
7. ↵
   1. Yazdi HH,
   2. Janahmadi M,
   3. Behzadi G

   (2007) The role of small-conductance Ca2+-activated K+channels in the modulation of 4-aminopyridine-induced burst firing in rat cerebellar Purkinje cells. Brain Res 1156, 59–66.
8. ↵
   1. Haghdoost-Yazdi H,
   2. Janahmadi M,
   3. Behzadi G

   (2008) Iberiotoxin-sensitive large conductance Ca2+-dependent K+(BK) channels regulate the spike configuration in the burst firing of cerebellar Purkinje neurons. Brain Res 1212, 1–8.
9. ↵
   1. Glasauer S,
   2. Strupp M,
   3. Kalla R,
   4. Buttner U,
   5. Brandt T

   (2005) Effect of 4-aminopyridine on upbeat and downbeat nystagmus elucidates the mechanism of downbeat nystagmus. Ann N Y Acad Sci 1039, 528–531.
10. ↵
    1. Strupp M,
    2. Kalla R,
    3. Glasauer S,
    4. Wagner J,
    5. Hufner K,
    6. Jahn K,
    7. et al.

    (2008) Aminopyridines for the treatment of cerebellar and ocular motor disorders. Prog Brain Res 171, 535–541.
11. ↵
    1. Haghdoost-Yazdi H,
    2. Faraji A,
    3. Fraidouni N,
    4. Movahedi M,
    5. Hadibeygi E,
    6. Vaezi F

    (2011) Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson’s disease. Behav Brain Res 223, 70–74.
12. ↵
    1. Paxinos G,
    2. Watson C

    , eds (2006) The Rat Brain in Stereotaxic Coordinates (Academic Press, San Diego (US)).
13. ↵
    1. Borlongan CV,
    2. Randall TS,
    3. Cahill DW,
    4. Sanberg PR

    (1995) Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test. Brain Res 676, 231–234.
14. ↵
    1. Moridi H,
    2. Karimi J,
    3. Sheikh N,
    4. Goodarzi MT,
    5. Saidijam M,
    6. Yadegarazari R,
    7. et al.

    (2015) Resveratrol-dependent down-regulation of receptor for advanced glycation end-products and oxidative stress in kidney of rats with diabetes. Int J Endocrinol Metab 13, e23542.
15. ↵
    1. Yuan H,
    2. Sarre S,
    3. Ebinger G,
    4. Michotte Y

    (2005) Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson’s disease. J Neurosci Methods 144, 35–45.
16. ↵
    1. Abrous DN,
    2. Rodriguez JJ,
    3. Montaron MF,
    4. Aurousseau C,
    5. Le Moal M,
    6. Barneoud P

    (1998) Behavioural recovery after unilateral lesion of the dopaminergic mesotelencephalic pathway:effect of repeated testing. Neuroscience 84, 213–221.
17. ↵
    1. Borlongan CV,
    2. Sanberg PR

    (1995) Elevated body swing test:a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci 15, 5372–5378.
18. ↵
    1. Wu ZZ,
    2. Li DP,
    3. Chen SR,
    4. Pan HL

    (2009) Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit. J Biol Chem 284, 36453–36461.
19. ↵
    1. Hayes KC

    (2004) The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev 10, 295–316.
20. ↵
    1. Leung G,
    2. Sun W,
    3. Brookes S,
    4. Smith D,
    5. Shi R

    (2011) Potassium channel blocker, 4-aminopyridine-3-methanol, restores axonal conduction in spinal cord of an animal model of multiple sclerosis. Exp Neurol 227, 232–235.
21. ↵
    1. Franciosi S,
    2. Ryu JK,
    3. Choi HB,
    4. Radov L,
    5. Kim SU,
    6. McLarnon JG

    (2006) Broad-spectrum effects of 4-aminopyridine to modulate amyloid beta1-42-induced cell signaling and functional responses in human microglia. J Neurosci 26, 11652–11664.
22. ↵
    1. McBride JM,
    2. Smith DT,
    3. Byrn SR,
    4. Borgens RB,
    5. Shi R

    (2006) Dose responses of three 4-aminopyridine derivatives on axonal conduction in spinal cord trauma. Eur J Pharm Sci 27, 237–242.
23. ↵
    1. Matsumoto S,
    2. Yoshida S,
    3. Takahashi M,
    4. Saiki C,
    5. Takeda M

    (2010) The roles of I(D), I(A) and I(K) in the electrophysiological functions of small diameter rat trigeminal ganglion neurons. Curr Mol Pharmacol 3, 30–36.